News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone – MD Anderson Cancer Center
Logo of MD Anderson Cancer Center from X
Oct 24, 2023, 13:44

MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone – MD Anderson Cancer Center

Quoting

“MD Anderson-led global Phase III study finds that a PARP inhibitor plus immunotherapy lowers the risk of endometrial cancer progression over chemotherapy alone.

“These findings showcase, for the first time, the potential of combining immunotherapy with a PARP inhibitor to deliver significant clinical improvements for these patients,” says lead investigator Shannon Westin.”

For more details click here.
cancer Endometrial cancer Headlines MD Anderson Cancer Center OncoDaily Oncology Shannon Westin
Special Coverage
Blog
Apr 15, 2025, 12:29
Wafaa M Rashed: Mutaz Mohamed on the urgent need to expand affordable genetic testing across African nations
Blog
Apr 15, 2025, 12:23
Conquer Cancer - Julie Gralow discusses how aspiring grant makers can utilize grant management services
Societies
Apr 15, 2025, 12:21
The Pediatric Oncology East and Mediterranean Group's (POEM) 4th Scientific Meeting
Blog
Apr 15, 2025, 12:18
Erick Mahatara: Almost 75% deaths in the world are due to NCDs, and the urgency around these diseases still seems too low
Blog
Apr 15, 2025, 12:17
Bernard A. Fox: Great commentary from Nature Medicine on vaccine hesitancy and the threat presented by the new leadership of HHS
Blog
Apr 15, 2025, 12:17
Duke Radiation Oncology - Olivia Franek presenting radiation oncology patient education videos project at ONS Congress
Blog
Apr 15, 2025, 12:08
Luis Lara-Mejía: Oncogenic fusions represent a diagnostic challenge across solid tumors
Blog
Apr 15, 2025, 12:02
Early registration is closing for the ESMO Gynaecological Cancers 2025
Blog
Apr 15, 2025, 11:54
Esosa Omoregie: Day 2 at ASBMB 2025 - Insights, networking, and career growth
Blog
Apr 15, 2025, 11:52
Diego A. Díaz García: Updates on the treatment of EGFR-mutant NSCLC
Career
Apr 15, 2025, 11:46
Merel Hennink has been appointed to the Board of Lung Cancer Europe
Oncolibrary
Apr 15, 2025, 11:34
New Paper Alert: Insights from the PALMARES-2 Study: Improved Outcomes with Abemaciclib and Ribociclib in HR+/HER2- ABC